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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYA large number of point mutations have been identified in induced pluripotent stem cell (iPSC) genomes to date. Whether these muta-
tions are associated with iPSC generation is an important and controversial issue. In this study, we approached this critical issue in
different ways, including an assessment of iPSCs versus embryonic stem cells (ESCs), and an investigation of variant allele frequencies
and the heterogeneity of point mutations within a single iPSC clone. Through these analyses, we obtained strong evidence that
iPSC-generation-associated point mutations occur frequently in a transversion-predominant manner just after the onset of cell lineage
conversion. The heterogeneity of the point mutation profiles within an iPSC clone was also revealed and reflects the history of the
emergence of each mutation. Further, our results suggest a possible approach for establishing iPSCs with fewer point mutations.INTRODUCTION
Induced pluripotent stem cells (iPSCs) hold great promise
for regenerative medicine (Lowry et al., 2008; Maherali
et al., 2007; Okita et al., 2007; Park et al., 2008; Takahashi
et al., 2007; Takahashi and Yamanaka, 2006; Wernig
et al., 2007; Yu et al., 2007), but their underlying molecular
mechanisms have remained elusive and several concerns
have arisen over their genomic integrity (Hussein et al.,
2013; Martins-Taylor and Xu, 2012; Puri and Nagy, 2012).
Thus far, investigators have studied the genomic stability
of iPSCs using various approaches (Hussein et al., 2011;
Laurent et al., 2011; Martins-Taylor et al., 2011; Mayshar
et al., 2010; Quinlan et al., 2011; Taapken et al., 2011),
and point mutation analyses of these cells were recently re-
ported (Cheng et al., 2012; Gore et al., 2011; Howden et al.,
2011; Ji et al., 2012; Young et al., 2012). A considerable
number of point mutations have been identified in iPSC
genomes, but a significant number of preexisting single
nucleotide variations (SNVs) have also been revealed in
the genomes of the parental somatic cells used to generate
iPSCs (Cheng et al., 2012; Gore et al., 2011; Ji et al., 2012;
Young et al., 2012). These results raise the question as to
whether the mutations identified in iPSC genomes are
age accrued and/or are due to reprogramming-associated
mechanisms. To date, most reports have supported the
notion of age-accrued, preexisting SNVs in parent somatic
cells (Cheng et al., 2012; Quinlan et al., 2011; Young et al.,
2012), although Ji et al. (2012) suggested that the substan-
tial mutations found in iPSCs cannot be accounted for by
preexisting mutations. To facilitate the clinical use of these52 Stem Cell Reports j Vol. 2 j 52–63 j January 14, 2014 j ª2014 The Authorstem cells and enhance our understanding of themolecular
mechanisms underlying the genome reprogramming pro-
cess, it is crucial to elucidate whether iPSC generation
causes a substantial number of point mutations. To address
this issue in our current study, we compared the point
mutation profiles in iPSCs with those in embryonic stem
cells (ESCs), and investigated variant allele frequencies
and the heterogeneity of point mutation profiles within
an iPSC clone to precisely determine the timing of the
occurrence of each point mutation.
RESULTS
iPSCs versus ESCs—a Considerable Difference in the
Frequency and Mode of Point Mutations
We compared the point mutation profiles in iPSCs with
those in ESCs. To exclude factors that could influence this
point mutation analysis, such as virus integration, age, cell
division, developmental ability, and culture conditions
(Martins-Taylor and Xu, 2012), we established ESC and
genome-integration-free iPSC lines (Okita et al., 2008)under
identical conditions, apart fromtheuseof feedercellsduring
ESC generation (Figure 1A). We examined three iPSC lines
(2A-4F-118, 2A-4F-119, and 2A-4F-136 [iPS118, iPS119,
and iPS136]) and four ESC lines (B6ES2-2, B6ES2-7, B6ES2-
9, and B6ES2-11 [ES2-2, ES2-7, ES2-9, and ES2-11]; Table S1
available online). These clones showed the expression of
stem cell markers, and germline transmission was verified
for most lines (Figures S1A and S1B; Araki et al., 2013).
To identify point mutations in a genome-wide fashion,
genome sequencing of the corresponding parent cells iss
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the parental cells is quite difficult and in humans in
particular is usually not feasible. Even in the case of
mouse ESCs, the use of an indirect control, such as an in-
dividual belonging to the same strain, can create a num-
ber of false positives during point mutation analysis,
including intrastrain SNPs. We therefore newly estab-
lished fully potent ESC lines and recovered the genomes
from both parents in advance (Figure 1A), which enabled
us to identify the point mutations that occurred during
ESC generation.
For the analysis of iPSCs, we used a mouse embryonic
fibroblast (MEF) fraction prepared from a single embryo
(Figure 1A). MEFs have been widely used in mouse iPSC
generation studies, and MEF fractions are always prepared
from multiple embryos, such as littermates, rather than
from a single embryo. This is due to the limited cell
numbers that can be obtained from a single embryo. How-
ever, the use of MEFs prepared from multiple embryos
frequently causes severe difficulties for subsequent point
mutation analysis because even in inbred strains, a number
of intrastrain SNPs will exist in the embryos. Hence, the use
of a MEF fraction from a single embryo is crucial for point
mutation analysis. We used MEF fractions prepared from a
single embryo for each iPSC generation: MEF2 (embryonic
day 13.5 [E13.5] embryo: No. 2) to establish lines iPS118
and iPS119, and MEF7 (E13.5 embryo: No. 7) for line
iPS136. In addition, to facilitate efficient sequence analysis,
we employed C57BL/6J mice, for which whole-genome
sequences have already been determined.
We performed genome sequencing using a paired-end
method with HiSeq 2000. More than 300 million reads
were obtained for each genome involving 94 or 100 bases
each, and more than 90% of the entire genome could be
covered using this method. In addition, 55% of each
genome could be sequenced with a high degree of redun-
dancy, by at least 10-fold (Figures S1C and S1D). Using
these sequences, we first predicted SNV candidates
in each genome through a comparison with reference
sequences of C57BL/6 (NCBI37/mm9), followed by a com-
parison of SNV candidates in the cell lines against those in
their corresponding parent cells. We found that 54.9%–
61.0% of the entire genomes were comparable, with a
high degree of redundancy (13.9–23.1 of the average read
depth; Figure S1C), and known SNPs were removed (Gore
et al., 2011; Wang et al., 2011).
Although it has been suggested that this level of read
depth is insufficient to remove false positives in a compre-
hensive identification of SNVs with bioinformatics only,
accurate identification is possible if additional criteria are
met (Ji et al., 2012). We therefore employed CLC software
and adopted some of its criteria to remove false positives
(Doan et al., 2012; Ghosh et al., 2012; Hayashida et al.,Stem2013; see Experimental Procedures; Figure S2A). Then, to
test our informatics screening, we performed Sanger
sequencing of 106 SNVs randomly selected from the pool
of candidates. All candidates were detected only in iPSCs
or ESCs in a heterozygous fashion, but none were observed
in their corresponding parent cells. We also performed
additional sequencing of some of the clones and their
parent cells. Although the depth of each read reached
29.9, 32.0, and 31.4 for iPS118, iPS136, and ES2-2, respec-
tively, the results did not differ from those obtained in
our first round of analysis with fewer redundancies (Table
S2), indicating that our sequencing approaches are suffi-
cient for genome-wide SNV identification from inbred
mouse genomes (Wartman et al., 2011). Moreover, we
also confirmed our results using GATK software, which is
currently widely used and is becoming a standard tool in
this field (McKenna et al., 2010; Table S3). The quality
scores of our SNV candidates and the SNP controls are
shown in Figure S2B. We thus concluded that almost all
of our candidates were true SNVs.
We finally identified 248 sites (per 1.41 3 109 bp) in
iPS118, 215 sites (per 1.56 3 109 bp) in iPS119, 281 sites
(per 1.42 3 109 bp) in iPS136, 37 sites (per 1.41 3 109 bp)
in ES2-2, 14 sites (per 1.42 3 109 bp) in ES2-7, 13 sites
(per 1.47 3 109 bp) in ES2-9, and 28 sites (per 1.50 3
109 bp) in ES2-11 as candidate point mutations (Figures
1B and S2A). Our data thus suggest the presence of a mark-
edly higher number of point mutations in iPSCs compared
with ESCs (Figure 1C). Itmust be noted, however, that even
the small number of mutations observed in ESCs could be
an overestimation since the livers of both parents were em-
ployed as references. Although the remaining cells, such as
trophectoderm cells in the blastocyst from which ESCs
were established, would be an ideal reference control, ex-
periments using such cells are beyond current technical
capabilities. If such experiments can be achieved in the
future, the mutation number in ESCs may in fact be found
to be lower than our current result.
A large number of mutations were also identified in the
intergenic regions, and little regional bias was observed
for the point mutations in the iPSC genomes (Figure S2C).
Details of the mutations we identified within the gene
regions of the stem cells analyzed are summarized in
Table S4. Importantly, only a few mutations were observed
within exons. We next performed a detailed breakdown
of all SNVs identified and then successfully identified
unique mutation profiles in the iPSC genomes. Only
21.6%–50.0% of the point mutations were found to be
transversions in ESCs. In contrast, more than 50% of the
point mutations detected in iPSCs were observed to be
transversions (54.0% for iPS118, 60.5% for iPS119, and
60.1% for iPS136 cells; Figure 1D). This is quite an
intriguing finding because most known point mutations,Cell Reports j Vol. 2 j 52–63 j January 14, 2014 j ª2014 The Authors 53
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Time Course of Point Mutation Occurrence in iPSCsincluding SNPs, exhibit transition-predominant profiles
(Figure S2D, right).
Variant Allele Frequency Analysis Reveals the
Heterogeneity of Point Mutation Profiles in iPSC
clones
We performed ultradeep-sequencing analysis on 26 of the
mutations identified in the iPS136 genome that were
randomly chosen to examine whether they existed in the
parent somatic cells (Gore et al., 2011; Ji et al., 2012). We
found that only one possible SNV out of the 26 analyzed
was detectable in the parental genome (Table S5). This
finding was not surprising given that the accumulation of
spontaneous mutations depends on the duration after
fertilization. Indeed, previous studies have reported ratios
of preexisting SNVs of 17/35 in newborns to 82-year-old
adults (human) (Gore et al., 2011), 8/46 in newborns
(human) (Ji et al., 2012), and 1/26 in E13.5 mouse embryos
(this study). Our current results thus strongly suggest that
substantial numbers of SNVs arise during iPSC generation.
However, it must be noted that even using ultradeep
sequencing, the number of somatic mutations in parental
somatic cells could be underestimated due to technical dif-
ficulties involved in performing this genotyping assay.
In addition, our ultradeep sequencing is limited by the
amount of startingmaterials due to the use ofMEFs derived
from a single embryo. Indeed, only 10,000 somatic cells
could be used for the analysis of each SNV candidate,
limiting the sensitivity of our analysis. Hence, to ascertain
whether iPSC generation processes cause point mutations,
methods other than the measurement of mutation inci-
dence in parental somatic cells were needed.
Therefore, we next conducted an allele frequency anal-
ysis of the iPSC clone iPS136, in which 43 SNV candidates
were examined by amplicon sequencing (Figure S3A). Our
aim was to identify the SNVs present at a <50% allele
frequency, which are considered to not be preexisting. As
anticipated, most SNVs showed 50% allele frequency;
however, significant numbers of SNVs (nine out of the 43
examined) were still observed at 12.5%–25% frequencies
(Figure S3A). Similar results were also observed in theFigure 1. Point Mutation Load in iPSCs versus ESCs
(A) Preparation of iPSC and ESC lines for point mutation analysis. Int
E13.5. Plasmids encoding the four required reprogramming factors we
E3.5 blastocysts. After three to four passages, the generated iPSCs an
(B) Distribution of base substitutions across mouse chromosomes. The
line across the chromosomes. Analysis of X and Y chromosomes could
sequences.
(C) Mutation rates. The bar graph represents the number of mutations
lines (blue).
(D) Mutation profiles of iPSCs and ESCs. The frequencies of transition
See also Figures S1, S2, and Tables S1–S5.
StemiPS118 genome (Figure S3B). Clearly, therefore, this is not
a rare event. Subsequently, to validate the presence of
25% SNVs and to estimate how many such SNVs exist
in iPSC genomes, we performed additional whole-genome
sequencing on the iPS136 cells up to a 25.2 redundancy
level on average, and expanded the lower limit of our
filtering from 35% to 10% to screen for 25% SNV candi-
dates (Figure S3C). From this sequencing, we successfully
identified a new peak of 25% in addition to the peak at
the 50% frequency (Figure 2A), and the number of 25%
SNV candidates was appreciable (105 candidates, 1/3 of
the number of 50% SNVs; Figure 2D). Subsequent ampli-
con sequencing confirmed this finding: when 46 of the
25% SNV candidates were randomly examined, almost all
(95.7%) exhibited a <50% allele frequency (groups II
and III; Figures 2B–2D).
The presence of a large number of 25% SNVs strongly
implied the heterogeneity of these variants within the
iPSC clone and indicated the occurrence of point muta-
tions during iPSC generation. To confirm this, we attemp-
ted to establish subclones of single-cell origin from the
iPS136 iPSC clone, which would enable us to investigate
individual cells within this clone. An additional aim of
this experiment was to exclude the possibility that 25%
SNVs identified in our screening were due to the contami-
nation of some preexisting iPSCs. We picked 96 single cells
from the colony of cells using a microcapillary pipette un-
der a microscope, and successfully established ten sublines
from these cells (Figure 3A). Using Sanger sequencing, we
examined these ten lines for five of the 50% SNVs,
including two SNV candidates (group I) as controls; 11 of
the 25% SNV candidates (group II); and ten of the <25%
candidates (group III) (Figures 2C and 3B). As anticipated,
each 50% SNV was observed in all sublines, indicating
that all subclones harbor wild/mutant alleles. In contrast,
no 25% SNVs were observed in any of the ten sublines.
Each candidate was observed only in about five of the
sublines. Nine out of the 11 25% SNVs were detected
only in the 136-A7, 136-A9, 136-B7, 136-D6, 136-E9, and
136-G2 sublines, but the remaining two candidates were
identified only in the remaining four sublines (136-A3,egration-free iPSCs were generated from a single mouse embryo at
re transfected into these cells and ESC lines were established from
d ESCs were collected.
dots indicate the positions of the point mutations identified in each
not be performed effectively due to the huge number of redundant
identified within the 13 109 bp genome of iPSC lines (red) and ESC
s and transversions are indicated by the pie charts.
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Figure 2. A Large Number of 25% SNVs
Are Present in the iPSC Genome
(A) Variant allele frequencies for SNV
candidates screened using high-coverage,
whole-genome sequencing data. The histo-
gram indicates the variant allele frequencies
by sequence coverage.
(B) Schematic representation of the
variant allele frequency test by amplicon
sequencing. The targeted variants were
amplified by PCR and assessed by deep
sequencing using an Illumina MiSeq.
(C) Variant allele frequency plots of 25%
SNV candidates in the iPS136 clone. The
plots show variant allele frequencies by
sequence coverage of amplicon sequencing.
The number of SNV candidates examined is
indicated in parentheses.
(D) Verification of candidate 25% SNVs.
See also Figure S3 and Table S1.
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Time Course of Point Mutation Occurrence in iPSCs136-D1, 136-F4, and 136-G11). Thus, the 25% SNV candi-
dates form two groups. The former nine candidates were
always observed together; however, although the latter
two candidates were also always observed together, each
subline had one of the two groups, but not both. Impor-
tantly, no subline had neither of the two groups, strongly
suggesting that these mutations arose just after the onset
of iPSC generation. Furthermore, all of the candidates in
group III, with a <25% allele frequency, existed in only
three sublines: 136-D1, 136-F4, and 136-G11.
We examined additional SNV candidates (62 in total) for
which PCR primers had been designed using three repre-
sentative sublines: 136-A3, 136-F4, and 136-D6 (Figure 3C,
upper panel). Whereas all 50% SNVs could be detected in
all sublines, 28 of the 25% SNV candidates were detected
in only one subline, 136-D6. The remaining five 25%
SNV candidates were observed in the other two sublines,
136-A3 and 136-F4, and all 22 of the <25% SNV candidates
were detected only in the 136-F4 subline. Thus, the time
course of point mutation occurrence in iPSCs was revealed,
and the possibility of contamination could be excluded
(Figure 3C, lower panel).
Our results thus reveal that 25% SNVs are generated just
after the first cell division from the onset of cell lineage con-
version from the parent somatic cell to iPSC. Furthermore,
each of the 12.5% SNVs was detectable in some of the sub-
lines, at roughly a 25% frequency, indicating that these
SNVs arise after the second cell division (Figure 3C, lower
panel). Moreover, the identification of more than one
hundred 25% SNVs strongly suggests the presence of at
least 158 of these SNVs in the iPS136 genome in total,
because the actual coverage of our current whole-genome
sequencing was approximately 63%.56 Stem Cell Reports j Vol. 2 j 52–63 j January 14, 2014 j ª2014 The AuthorTo validate our observations using the iPS136 clone, we
examined another integration-free iPSC clone, iPS118
(Figures 4A–4C). Fifty-nine 25% SNV candidates were iden-
tified by further sequencing of this additional clone, with a
23.5 level of redundancy on average (Figures 4A and S3C).
Twenty-three of these candidates were randomly selected
for subsequent amplicon sequencing, and most clearly ex-
hibited a <50% allele frequency, although four candidates
exhibited an50% frequency (Figure 4B). Finally, the pres-
ence of 25% SNVs was assessed through analysis of 13
sublines established from an iPS118 colony (Figure 4C).
We also investigated three additional iPSC clones (iPS119
[Figure 4D], R (retro)-4F-28 [iPS28; Figure 4E], and R-4F-29
[iPS29; Figure 4F]), including retrovirus-mediated iPSC
clones (Figure S4), using this subclone analysis. The results
confirmed that an appreciable number of25% SNVs exist
in all iPSC clones.DISCUSSION
After the identification of a large number of single-nucleo-
tide mutations in iPSC genomes, and regardless of the pro-
cedures used for their generation, the central question
regarding point mutations in iPSC genomes has shifted to
whether they arise through the actual generation process
or whether they can be explained by classical spontaneous
mutation events that occur mainly in their parental cells
(Hussein et al., 2013). Indeed, ultradeep-sequencing anal-
ysis of the parent cells of iPSCs has revealed the preexis-
tence of a proportion of SNV candidates (Gore et al.,
2011; Ji et al., 2012). In addition, a quite recent analysis
of sister iPSC clones also suggested the presence of manys
Stem Cell Reports
Time Course of Point Mutation Occurrence in iPSCspreexisting SNVs in parental somatic cells (Young et al.,
2012).
In our current study, we approached the issue of iPSC
point mutations from a series of unique angles, using
whole-genome sequencing as follows: (1) an assessment
of iPSCs versus ESCs, (2) an investigation of variant allele
frequencies, and (3) an investigation of the heterogeneity
of point mutation profiles in cells within an iPSC clone.
Taken together, our findings indicate that a substantial
number of point mutations in iPSCs occur in a transver-
sion-predominant manner during the conversion process,
especially at the initiation steps, from somatic cell to
iPSC. Our conclusion is consistent with the previous obser-
vation that 74% of the mutations found in iPSCs cannot
be accounted for by preexisting mutations or by acquisi-
tion during passage in culture (Ji et al., 2012).
To verify our present findings obtained by variant
allele frequency testing using extensive whole-genome
sequencing, and following amplicon sequencing, we devel-
oped a procedure to investigate the variant alleles in each
cell within an iPSC clonal population. This was achieved
by preparing single-cell-derived subclones from one iPSC
clone, and the results clearly demonstrated that point
mutations still arose after conversion to stem cells, and
particularly just after conversion from a somatic cell, at
a remarkably high rate. Interestingly, we also observed a
strong bias in the frequency of 25% and <25% SNVs among
sublines derived from the iPS136 clone: 28 in the 136-D6
sublineand27 in136-F4,butonlyfive in136-A3(Figure3C).
This tendency was also observed in other iPSCs examined
by subclone analysis (Figures 4C–4F). Thus, we believe
that our approach of focusing on single-cell-derived sub-
cloneswill shed lighton themechanismsunderlying thege-
netic aberrations associated with genome reprogramming.
To further determine the generality of our finding that
iPSCs harbor unique transversion-predominant point mu-
tation profiles (Figure S2D, left), we analyzed previously re-
ported point mutation profiles in 27 different iPSC lines
that had been established by various methods, including
retrovirus, plasmid, and mRNA methods (Gore et al.,
2011; Ji et al., 2012; Young et al., 2012; Figure S2E). We
hypothesized that only the point mutations caused by
iPSC generationwould exhibit a transversion-predominant
profile, and that other point mutations that arose before
and after iPSC generation would be transition predomi-
nant. When we compared the SNVs whose origin was
revealed (preexisting or occurring in prolonged culture)
with the remaining SNVs whose origin was not revealed,
we clearly observed a transversion preference in the re-
maining SNVs, but not in somatic cells prior to reprogram-
ming or in iPSCs in prolonged culture (Figure S2E). Hence,
the fact that an iPSC-generation-associated, transversion-
predominant point mutation profile is widely observedStemin iPSCs of various origins indicates that this is a general
iPSC-generation-associated phenomenon that is not
limited to our current investigation (Figure S2D, left).
In this study, we employed single-embryo-derived MEF
lines (MEF2 andMEF7) for iPSC generation. This is an ideal
system for identifying de novo point mutations because
novel intrastrain SNPs will not be incorrectly designated
as point mutations. In our analyses, we performed whole-
genome sequencing for two and four iPSC clones derived
from the MEF2 and MEF7 lines, respectively. A large num-
ber of SNV candidates (2,169) were identified in total, but,
interestingly, no common SNVwas observed among the six
iPSC clones. Although two common SNVs, chr1_54465821
and chrX_30378169, were suggested between the iPS136
and iPS28 lines, both candidates turned out to be located
in the repetitive regions LTR and LINE, strongly suggesting
that these SNVs were detected by mapping errors. Thus, all
SNVs identified in our analysis were clone specific (Figures
5 and S4). Our results strongly suggest that all of the SNV
candidates we identified in iPSC genomes, including 50%
SNVs for which we could not directly demonstrate an asso-
ciation with iPSC generation by variant allele frequency
analysis or subclone analysis, are also not preexisting. In
addition, our observations do not support the elite hypoth-
esis that iPSCs can be converted from certain somatic cells.
To enable future medical applications of these cells, it is
crucial to determine the entire mutation load of iPSC ge-
nomes. Although we initially focused on 50% SNVs (Fig-
ure 1), since we could not expect a presence of 25% SNVs
in the early stages of our study, this resulted in a substantial
underestimation of the point mutation load per genome.
Subsequently, we successfully identified a substantial num-
ber of %25% SNVs, although this was smaller than the
number of 50% SNVs (Figures 2A and 4A). Needless to
say, even with our current estimation, the number of
SNVs, especially those of%25% frequency, could be under-
estimated due to read-depth limitations. Thus, the SNVs
reported herein represent a conservative estimate and the
true SNV number per cell line could well be higher. Deter-
mining the entire point mutation load in iPSC genomes
thus remains an important and challenging goal.
Our present findings raise serious concerns regarding the
potential clinical use of iPSCs. In fact, several iPSC point
mutations were identified within exons (n = 2–4 SNVs for
integration-free iPSCs and 5–9 SNVs for the iPSCs gener-
ated using retrovirus vector), and most SNVs within gene-
coding regions were found to be nonsynonymous, which
supports previous findings (Gore et al., 2011; Howden
et al., 2011; Figure S2C; Table S4). Although all of these
SNVs were found to be heterozygous in nature, we cannot
completely rule out the possibility that these SNVs can
cause abnormalities such as tumors. Hence, careful investi-
gations of these variants are still needed. Based on ourCell Reports j Vol. 2 j 52–63 j January 14, 2014 j ª2014 The Authors 57
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Time Course of Point Mutation Occurrence in iPSCsfindings, we propose an approach to enable the production
of iPSCswith fewer pointmutations that involves the selec-
tion of sublines that harbor only small numbers of such
mutations.EXPERIMENTAL PROCEDURES
Establishment of iPSCs and ESCs
Animal experimentswere performed in accordancewith the guide-
lines of the National Institute of Radiological Sciences Animal
Care and Use Committee. We employed the mouse inbred strain
C57BL/6J for the preparation of all cell lines. We used MEF frac-
tions prepared from a single embryo for iPSC generation. The
four iPSC lines prepared from MEF7 were iPS136, iPS28, iPS29,
and R-4F-32 (iPS32), and the two lines derived from MEF2 were
iPS118 and iPS119 (Figure 5; Table S1). Yamanaka factors Oct4,
Sox2, KLF4, and c-Myc (4F) were introduced using either plasmid
or retrovirus vectors. Establishment of the integration-free iPSC
lines iPS118, iPS119, and iPS136, and the ESC lines ES2-2 and
ES2-9 has been reported elsewhere (Araki et al., 2013). Other ESC
lines were established as previously described (Nagy et al., 1993).
The iPS28, iPS29, and iPS32 clones were established with 4F in
retroviral vector (Takahashi and Yamanaka, 2006).
After the establishment of clones, we confirmed the integration
of all retroviral transgenes into the genome of each clone, and the
independence of the clones. Stem cell markers and karyotypes
were confirmed for all lines, and germline transmission of the
chimeric mice was confirmed for most of the lines, including
ESCs, shown in Figure 1 (iPS118, iPS119, iPS136, ES2-2, and
ES2-9; Araki et al., 2013).
Immunocytochemistry
For immunocytochemical staining, anti-Nanog (1:50; ReproCELL),
anti-Oct3/4 h-134 (1:100; Santa Cruz Biotechnology), and anti-
Sox-2 Y-17 (1:100; Santa Cruz) antibodies were used.
Whole-Genome Sequencing
DNAwas extracted using theDNeasy Blood&Tissue Kit (QIAGEN).
Illumina libraries were prepared and all sequencing was performed
using a HiSeq 2000 sequencer (Illumina) with 94 or 100 bases 3 2
(paired-end) reads.Figure 3. Heterogeneity of Point Mutation Profiles in an iPSC Clo
(A) Single-cell isolation and establishment of sublines from a single
(B) Point mutation profiles of each subline. The positions of five 50%
SNVs (group III) were examined through sequence patterns (Sanger se
G2, and G11), original iPS136 cells, and parental somatic cells. The p
different colors (green, controls + group I; orange, group II; purple,
(C) Time course of point mutation occurrence in iPSCs. Upper panel:
three representative sublines of the iPS136 clone (136-A3, F4, and D6
in iPS136 sublines. These point mutation profiles indicate that 50
mutations that had occurred just after the onset of stem cell conversio
were generated after the first and second cell divisions, respectively. Th
occurred and were detectable in this experiment.
See also Table S1.
StemRead Mapping and SNV Calling
The obtained reads were mapped onto the mouse reference
genome (NCBI37/mm9) using BWA (version 0.5.9; Li and Durbin,
2009).We permitted 2 basemismatchmapping, and only uniquely
mapped reads were retained for SNV analysis. SNV calling was car-
ried out on a CLC Genomics Workbench (CLC bio). The parame-
ters were set as follows: window length, 11; maximum gap and
mismatch count, 2; minimum quality of central base, 30; mini-
mum average quality of surrounding bases, 15. To detect as
many candidates as possible, genomic regions with at least 4 3
coverage were targeted, and positions with a mutant allele fre-
quency of >35% were listed as an SNV candidate in the iPSC and
ESC lines. To detect the presence of possible SNVs in donor embryo
and parental mice genomes, positions with a mutant allele fre-
quency of >10% were listed. SNVs that appeared within the unor-
dered sequences (random sequences) of the reference mouse
genome, which are known to be on a particular chromosome but
could not be ordered, were excluded from the panel of candidates.
To detect SNVs with a frequency of <25%, SNV calling was per-
formed using high-coverage sequencing data for both the iPSC
and donor embryo genomes. The parameters were set as follows:
window length, 11; maximum gap and mismatch count, 2; mini-
mum quality of central base, 35; minimum average quality of sur-
rounding bases, 25; minimumcoverage, 10; andminimumvariant
frequency (%), 10.
To validate our analysis using theCLCGenomicsWorkbench, we
also performed SNVdetection usingGATK (GenomeAnalysis Tool-
kit v.1.6). The quality scores for the mapped reads were recali-
brated, and PCR duplicates were removed using Picard (v.1.74).
We then realigned the reads and identified SNVs under a minimal
quality (QUAL in GATK) of 30.
Identification of Mutations Generated during the
Derivation of iPSCs and ESCs
Candidate mutations were defined as variants present in the iPSC
or ESC genome, but not in the donor embryo or parental mice,
respectively. As a first screening step, we discarded candidates if
they were present in the genome of the corresponding reference
(the donor embryo for iPSCs and the parental mice for ESCs)
with a frequency of >10%. To reduce the false-positive rate,
variants present in the mouse dbSNP database (v. 128) were
excluded. In addition, because a novel mutation acquired duringne
iPSC clone.
SNVs (controls + group I), 11 25% SNVs (group II), and ten <25%
quencing) in sublines of iPS136 (136-A3, A7, A9, B7, D1, D6, E9, F4,
ositions in which mutant alleles were detected are indicated with
group III). nd, not determined.
sequence patterns of a total of 62 positions that were examined in
). Lower panel: conclusions from the point mutation profile analysis
% SNVs (Nos. 1–7) were potentially preexisting parental SNVs or
n. In contrast, 25% SNVs (Nos. 8–40) and <25% SNVs (Nos. 41–62)
e values in parentheses indicate the total number of mutations that
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Figure 4. Heterogeneity of the Point Mutation Profiles in Other iPSC Clones
(A) Variant allele frequencies for SNV candidates screened using high-coverage, whole-genome sequencing data for the iPS118 line.
(B) Variant allele frequency plots of 25% SNV candidates of iPS118 cells. The plots show variant allele frequencies determined by sequence
coverage of amplicon sequencing. The number of SNV candidates examined is indicated in parentheses.
(C) Point mutation profiles of sublines of iPS118. Sequence patterns of a total of 22 positions were examined in 13 subclones of iPS118.
(D) Point mutation profiles in sublines of iPS119. Sequence patterns of a total of 12 positions were examined in 12 subclones of iPS119.
(E) Point mutation profiles in sublines of iPS28. Sequence patterns of a total of 14 positions were examined in 12 subclones of iPS28.
(F) Point mutation profiles in sublines of iPS29. Sequence patterns of a total of five positions were examined in 11 subclones of iPS29.
See also Table S1.
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Time Course of Point Mutation Occurrence in iPSCsreprogramming is unlikely to occur homozygously, we selected the
positions in which the mutant alleles have been detected at a fre-
quency of 35%–65%. Because low sequencing depth can lead to60 Stem Cell Reports j Vol. 2 j 52–63 j January 14, 2014 j ª2014 The Authorfalse positives, variants that were positioned in genomic regions
sequenced at a minimal read depth of 10–173 in both samples
(iPSC or ESC) and in the corresponding reference genome (donors
embryo: No.2
MEF2
(248)
2A-4F-118
(215)
2A-4F-119
embryo: No.7
MEF7
(281)
2A-4F-136
(497)
R-4F-28
(574)
R-4F-29
(354)
R-4F-32
No common SNVs among iPSCs
Figure 5. No Common SNVs Exist among iPSCs Generated from
Single Embryo-Derived MEFs
The number of SNVs identified is shown in parentheses.
See also Figure S4 and Table S1.
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Time Course of Point Mutation Occurrence in iPSCsembryo or parental mice) were used for the comparison between
iPSC and ESC lines. To remove SNVs that probably had occurred
due to sequencing and mapping errors, we discarded candidates
that were detected near the beginning and end of the reads and
were located close to simple repeat sequences. To reduce the num-
ber of false positives introduced by mapping error, variants coded
only by single (broken-paired) reads and mapped reads, including
two-linked variants within a 94–100 bases read were removed.
Finally, sites in which the embryo or parental genome included
even one read with a mutant allele were removed as candidates
for novel mutation sites, and several positions were identified in
which the mouse iPSC or ESC samples showed a heterozygous
pattern but their parental sample showed a homozygous pattern
in a shared high-quality sequenced region. The mutation rate
was expressed as the number of mutations per 109 bp of each
iPSC or ESC genome.
To identify mutations present at low frequencies in the iPSC
genome, we screened candidates in a similar manner as described
above, with two modifications: (1) we selected the variants that
were positioned in genomic regions sequenced at a minimum
read depth of 213 in both the iPSC and donor embryo genomes,
and (2) a screening step based on the frequency of the mutant
alleles was omitted, and the positions in which the number of
mutant allele reads was >53 were targeted as candidates for muta-
tion sites.
Sanger Validation of Candidate Mutations
Genomic DNAs were amplified using primer sets that had been
specifically designed around the candidate mutation sites. PCRStemreactions were performed using Titanium Taq DNA polymerase
(TAKARA BIO), and PCR products were directly sequenced using
a 3730 DNA Analyzer (Life Technologies).
Deep Sequencing
Amplicon sequencing was performed as previously described
(Gore et al., 2011). Target regions were amplified with high-fidelity
Taq polymerase, PrimeSTAR GXL DNA Polymerase (TAKARA
BIO). Mixed PCR products were ligated to Illumina paired-end
sequencing adapters and sequenced using the HiSeq 2000
sequencer.
Variant Allele Frequency Analysis
Genomic regions containing target SNV sites were amplified with
Titanium Taq DNA polymerase (TAKARA BIO). PCR products
were mixed and purified using the MinElute PCR Purification Kit
(QIAGEN), and the sequences were determined using the Ion
Torrent PGM sequencer with the Ion 316 chip (Life Technologies)
and MiSeq sequencer (Illumina).
Subclone Analysis
iPSCs were trypsinized and single cells were transferred one by
one with a microcapillary pipette to individual wells of a 96-well
plate with feeder cells. After 1 week in culture, single colonies
were transferred into new 24-well plates without feeder cells.
Genomic DNAs were then prepared from the cells and used for
Sanger sequencing.
ACCESSION NUMBERS
Raw Illumina sequencing reads are available from the DDBJ
Sequence Read Archive under accession number DRA000524.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and five tables and
can be found with this article online at http://dx.doi.org/10.1016/
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